Full-Time

Director – Patient Services

HUB & Field Access Operations

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$215k - $260kAnnually

+ Performance Bonus + Equity

Senior

San Francisco, CA, USA

30 - 40% travel is required.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BA/BS degree required; MBA preferred
  • Minimum of 8-10 years of Biotech/Pharma experience
  • Cardiology, Pediatric, Oncology, and Rare Disease experience are preferred
  • Strong communication and interpersonal skills
  • Ability to work independently and in a team environment
  • Must have a strong foundation and experience working closely with patient support programs, including copay, cost-sharing programs, affordability design, and hub models for medical and pharmacy benefit products
  • Comprehend the complex environment of the specialty market, buy and bill, reimbursement/access challenges, as well as the OIG/CMS/legal guidelines for offering a patient support program
  • Demonstrate excellent analytical skills and the ability to develop sound strategies in response to  patient access
  • Previous experience directly managing patient and provider support hub or services to ensure patient access to treatment
  • Exhibit superior communication (oral and written) and teamwork skills to effectively contribute across cross-functional teams
  • Training experience is a plus
  • Extremely detail-oriented oriented to create and manage program documents
  • Experience establishing and maintaining high-level relationships with key decision-makers
Responsibilities
  • Assist and lead in the development of patient support programs under the branding of ForgingBridges, which result in a positive customer experience
  • Support all new product and program launch implementation activities
  • Implement new access initiatives/programs
  • Participate in the strategic planning for upcoming launches, launch meetings, market access team meetings, and other opportunities to interact with management and senior management in the organization
  • Partner with the Market Access Marketing/Brand Marketing team to identify promotional collateral which would provide value to the patient community
  • Ensure programs and materials comply with direction from Medical, Legal & Regulatory (MLR)
  • Manage day-to-day operations for fully launched patient support programs
  • Has oversight of contracts and partnerships with patient support program vendors (copay, free goods pharmacy, hub, etc.)
  • Create and coordinate smooth communications handoff process between hub, PAL/FRM teams
  • Monitor Key Performance Indicators (KPIs) and Service Level Agreements (SLAs) to ensure vendors are meeting goals
  • Manage vendor and internal PAL/FRM business rules/operations procedure documents, including drafting, as needed and partnering with legal/compliance for review and implementation
  • Ensure program compliance with program business rules/operation procedures through regular auditing of cases/phone calls
  • Coordinate weekly status calls and follow-ups with internal/external stakeholders
  • Serve as a day-to-day liaison with field teams, marketing and sales managers, and other stakeholders, which include resolving escalation issues
  • Train internal stakeholders on the patient support program and PAL/FRM processes and rules of engagement
  • Review and analyze data reporting from the vendors to identify issues, trends, and potential interventions to ensure program excellence
  • Stay connected with BridgeBio Commercial Analytics and Commercial IT on the internal CRM and PAL/FRM reports & dashboards & external CRM, and accounts activity tracking
  • Serve as a backup to the Head of Patient Services to lead and make decisions on support programs and PAL/FRM operations
  • Work closely with the Head of Patient Services to resolve any issues and implement new program initiatives PAL/FRM activity, and ensure integration of marketing strategies and goals are consistently communicated across all vendor partners and materials for HCP, pharmacy, and patient audiences
  • Provide regular updates and analysis of patient programs and field access to the Head of Patient Services
  • Attend patient meetings and represent BridgeBio at industry conferences
  • Other additional responsibilities may be assigned
  • Travel to sales meetings and medical offices as necessary
  • 30 - 40% travel is required

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. The company generates revenue through drug development, licensing agreements, and partnerships, with a diverse pipeline of over 15 drug programs aimed at 20 different genetic diseases. Their culture promotes independent thinking and transparency, enabling quick, data-driven decisions that enhance their drug development process.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

28%

1 year growth

59%

2 year growth

97%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.

Help us improve and share your feedback! Did you find this helpful?